226 related articles for article (PubMed ID: 19211791)
1. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.
Guillonneau C; Mintern JD; Hubert FX; Hurt AC; Besra GS; Porcelli S; Barr IG; Doherty PC; Godfrey DI; Turner SJ
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3330-5. PubMed ID: 19211791
[TBL] [Abstract][Full Text] [Related]
2. Recalling the Future: Immunological Memory Toward Unpredictable Influenza Viruses.
Auladell M; Jia X; Hensen L; Chua B; Fox A; Nguyen THO; Doherty PC; Kedzierska K
Front Immunol; 2019; 10():1400. PubMed ID: 31312199
[TBL] [Abstract][Full Text] [Related]
3. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells.
Day EB; Zeng W; Doherty PC; Jackson DC; Kedzierska K; Turner SJ
J Immunol; 2007 Aug; 179(4):2187-94. PubMed ID: 17675478
[TBL] [Abstract][Full Text] [Related]
4. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.
Reilly EC; Thompson EA; Aspeslagh S; Wands JR; Elewaut D; Brossay L
PLoS One; 2012; 7(5):e37991. PubMed ID: 22649570
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
Kamijuku H; Nagata Y; Jiang X; Ichinohe T; Tashiro T; Mori K; Taniguchi M; Hase K; Ohno H; Shimaoka T; Yonehara S; Odagiri T; Tashiro M; Sata T; Hasegawa H; Seino KI
Mucosal Immunol; 2008 May; 1(3):208-18. PubMed ID: 19079180
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.
Dwivedi V; Manickam C; Dhakal S; Binjawadagi B; Ouyang K; Hiremath J; Khatri M; Hague JG; Lee CW; Renukaradhya GJ
Vet Microbiol; 2016 Apr; 186():157-63. PubMed ID: 27016770
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
8. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
9. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.
Kopecky-Bromberg SA; Fraser KA; Pica N; Carnero E; Moran TM; Franck RW; Tsuji M; Palese P
Vaccine; 2009 Jun; 27(28):3766-74. PubMed ID: 19464560
[TBL] [Abstract][Full Text] [Related]
10. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
[TBL] [Abstract][Full Text] [Related]
11. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
[TBL] [Abstract][Full Text] [Related]
12. In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.
Fernandez CS; Jegaskanda S; Godfrey DI; Kent SJ
Clin Exp Immunol; 2013 Sep; 173(3):480-92. PubMed ID: 23656283
[TBL] [Abstract][Full Text] [Related]
13. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
14. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
15. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
17. Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.
Anderson RJ; Li J; Kedzierski L; Compton BJ; Hayman CM; Osmond TL; Tang CW; Farrand KJ; Koay HF; Almeida CFDSSE; Holz LR; Williams GM; Brimble MA; Wang Z; Koutsakos M; Kedzierska K; Godfrey DI; Hermans IF; Turner SJ; Painter GF
ACS Chem Biol; 2017 Nov; 12(11):2898-2905. PubMed ID: 29043774
[TBL] [Abstract][Full Text] [Related]
18. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
[TBL] [Abstract][Full Text] [Related]
19. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
20. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
